Citadel Advisors
ODT

Citadel Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Citadel Advisors’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68,800
Closed -$240K – 15179
2021
Q2 		$240K Sell
68,800
-16,600
-19% -$57K ﹤0.01% 11781
2021
Q1 		$292K Buy
85,400
+15,200
+22% +$287K ﹤0.01% 10928
2020
Q4 		$1.35M Sell
70,200
-18,900
-21% -$292K ﹤0.01% 6157
2020
Q3 		$1.2M Buy
89,100
+83,100
+1,385% +$2.35M ﹤0.01% 5706
2020
Q2 		$254K Buy
+6,000
New +$194K ﹤0.01% 8183

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's ODT Position: Q1 2022 in Review

Citadel Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 10,397 shares — an estimated $14K sold.

Citadel Advisors first reported a position in ODT in Q4 2018 and held it in 11 quarters. The position peaked at $1.94M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Citadel Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 10,397 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $14K.
  • Citadel Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
  • Citadel Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $1.94M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.